Cilnidipine/valsartan - Ajinomoto/Mochida

Drug Profile

Cilnidipine/valsartan - Ajinomoto/Mochida

Alternative Names: AJH-801; Atedio; Valsartan/cilnidipine

Latest Information Update: 31 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ajinomoto Pharma; Mochida Pharmaceutical
  • Developer Ajinomoto Pharma; Ildong Pharmaceutical; Mochida Pharmaceutical
  • Class Antihypertensives; Branched-chain amino acids; Dihydropyridines; Small molecules; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypertension

Most Recent Events

  • 01 Sep 2015 IlDong Pharmaceutical completes phase-III clinical trials in Hypertension in South Korea (PO) (NCT02145104; KCT0001947)
  • 15 Jan 2015 Ildong Pharmaceutical plans a phase I bioequivalence trial in Healthy volunteers in South Korea (NCT02343250)
  • 31 May 2014 Launched for Hypertension in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top